Promethazine/sumatriptan - Charleston Laboratories

Drug Profile

Promethazine/sumatriptan - Charleston Laboratories

Alternative Names: CL-H1T

Latest Information Update: 05 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Charleston Laboratories
  • Class Antiemetics; Antimigraines; Indoles; Small molecules; Sulfonamides
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Migraine; Nausea and vomiting

Most Recent Events

  • 05 Feb 2016 Phase-II clinical trials in Migraine in USA (PO)
  • 05 Feb 2016 Phase-II clinical trials in Nausea and vomiting in USA (PO)
  • 03 Aug 2015 Phase-I clinical trials in Migraine in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top